Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Strut Health provides compounded semaglutide through licensed 503A pharmacies, making GLP-1 therapy more accessible. However, choosing a compounded semaglutide source requires understanding dosing protocols, clinical oversight, and whether your individual physiology aligns with GLP-1 therapy.

Personalized GLP-1 treatment extends beyond brand selection. Biomarkers—such as fasting glucose, insulin resistance, and GLP-1 receptor sensitivity markers—and genetic predispositions in peptide pathways can help guide whether compounded semaglutide is right for you and at what dose to begin.

What Compounded Semaglutide Is and How It Differs from Branded Options

Compounded semaglutide is manufactured by licensed 503A compounding pharmacies under strict pharmaceutical standards. Unlike branded Ozempic or Wegovy, compounded versions are customized formulations created by the pharmacy for individual patients.

Both compounded and branded semaglutide use the same active ingredient and mechanism: GLP-1 receptor agonism to reduce appetite and improve glycemic control. The key difference is cost, supply flexibility, and regulatory pathway—compounded medications do not carry FDA approval as finished products but are prepared under established pharmacy practice standards.

Dosing Protocols and Clinical Oversight in Compounded Semaglutide Programs

Reputable compounded semaglutide providers, including Strut Health, typically follow a titration schedule: starting at 0.25 mg weekly, escalating to 0.5 mg, 1 mg, and higher based on tolerance and clinical response. Medical supervision is essential to monitor efficacy and side effects.

Dosing decisions should consider baseline metabolic markers, prior medication responses, and individual risk factors. A qualified provider should assess fasting glucose, BMI, kidney function, and gastrointestinal history before initiating therapy and adjust dose based on clinical progress.

Clinical Factor Relevance to Compounded Semaglutide Dosing
Fasting Glucose / HbA1c Establishes baseline glycemic control; informs whether GLP-1 is appropriate and initial dose decision
Insulin Resistance (HOMA-IR) Predicts metabolic response to GLP-1; higher resistance may warrant more gradual titration
Renal Function (eGFR) GLP-1 dosing may require adjustment in moderate to severe renal impairment
Gastrointestinal History Prior GERD, pancreatitis, or gastroparesis may contraindicate or require cautious dosing with GLP-1 agonists
BMI and Weight Loss History Baseline BMI and prior weight loss attempts inform realistic expectations and dose escalation pacing

Genetic Predispositions in GLP-1 Pathway Responsiveness

Emerging research identifies genetic variants in the GLP-1 receptor gene (GLP1R rs6923761) and GIPR rs1800437 that may influence how individuals respond to GLP-1 agonist therapy. These predispositions do not determine outcome but can help provide context for your provider's dosing and monitoring strategy.

Variants in FTO rs9939609 and MC4R rs17782313 relate to appetite regulation and weight loss potential. Individuals with certain allele combinations may experience more pronounced satiety or metabolic shifts on GLP-1 therapy, suggesting a need for individualized titration and follow-up intervals.

Safety, Eligibility, and Provider-Guided Decision-Making

Compounded semaglutide is not appropriate for patients with personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, acute pancreatitis, or diabetic retinopathy requiring urgent ophthalmology consultation. A thorough medical history is non-negotiable before therapy initiation.

Common side effects include nausea, vomiting, diarrhea, and constipation—usually transient and dose-dependent. Serious but rare adverse events include pancreatitis and gallbladder complications. Your provider should establish clear follow-up intervals, monitor for warning symptoms, and adjust dosing based on tolerance and efficacy markers rather than arbitrary schedules.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for your GLP-1 receptor pathway predispositions by analyzing variants like GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These insights should be interpreted with a qualified healthcare provider to inform whether compounded semaglutide aligns with your genetic and metabolic profile.

The genetic test reveals predispositions in peptide regulatory pathways, not exact medication response. A patient carrying favorable GLP1R or GIPR variants may experience stronger appetite suppression, while those with FTO or MC4R variants might show variable weight loss trajectories—yet individual clinical and lifestyle factors remain decisive.

Combining biomarker assessment (fasting glucose, insulin resistance, kidney function) with genetic predisposition insights can support a more informed conversation with your provider about whether compounded semaglutide is suitable, what starting dose makes sense, and how closely to monitor early response.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide from providers like Strut Health as effective as branded Ozempic or Wegovy?

Both use the same active ingredient and mechanism. Efficacy depends on dose, adherence, medical supervision, and individual physiology—not brand. Licensed 503A compounding pharmacies maintain quality standards, but your provider's oversight is critical.

What biomarkers should I check before starting compounded semaglutide?

Fasting glucose, HbA1c, insulin resistance (HOMA-IR), lipid panel, renal function (eGFR), liver function, and pancreatic enzymes establish baseline health. Your provider should review these and gastrointestinal history before initiating therapy.

How does PlexusDx's compounded semaglutide pricing compare to Strut Health?

PlexusDx offers compounded semaglutide from $149/mo through licensed 503A pharmacies. Your actual cost depends on dose, supply, and insurance coverage. Request a personalized quote to compare options.

What are the most common side effects of compounded semaglutide, and when do they resolve?

Nausea, constipation, and diarrhea are typical, especially during titration. Most resolve within 1–2 weeks. Notify your provider if symptoms persist, worsen, or include abdominal pain or signs of pancreatitis.

Can the Precision Peptide Genetic Test predict whether I'll respond well to semaglutide?

No. The test identifies predispositions in GLP1R, GIPR, FTO, and MC4R pathways but does not predict exact medication response. Combined with biomarker data and clinical history, it may support a more personalized treatment discussion with your provider.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves